Amneal Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell AMRX and other ETFs, options, and stocks.About AMRX
Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog.
CEOChintu Patel
CEOChintu Patel
Employees7,850
Employees7,850
HeadquartersBridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded2002
Founded2002
Employees7,850
Employees7,850
AMRX Key Statistics
Market cap2.69B
Market cap2.69B
Price-Earnings ratio-12.24
Price-Earnings ratio-12.24
Dividend yield—
Dividend yield—
Average volume1.57M
Average volume1.57M
High today$8.70
High today$8.70
Low today$7.61
Low today$7.61
Open price$7.96
Open price$7.96
Volume2.85M
Volume2.85M
52 Week high$9.48
52 Week high$9.48
52 Week low$5.01
52 Week low$5.01
AMRX News
Benzinga 9h
Generic Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, BiosimilarsOn Friday, Amneal Pharmaceuticals Inc. AMRX reported fourth-quarter adjusted EPS of 12 cents, down from 14 cents a year ago and missing the consensus of $0.15....
Benzinga 4d
Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades StockJ.P. Morgan has upgraded Amneal Pharmaceuticals, Inc AMRX, noting the company’s generics business is increasingly well-positioned with a solid Crexont launch an...
Seeking Alpha 4d
Amneal stock climbs 10% amid J.P. Morgan upgradeShares of Amneal Pharmaceuticals (NASDAQ:AMRX) rose 10% on Monday after J.P. Morgan raised its rating on the stock to overweight from neutral, based on in part...
More AMRX News
TipRanks 4d
Amneal Pharmaceuticals upgraded to Overweight from Neutral at JPMorganJPMorgan upgraded Amneal Pharmaceuticals (AMRX) to Overweight from Neutral with a price target of $12, up from $9. The firm cites the Crexont launch being off t...